Genome editing for inborn errors of metabolism: advancing towards the clinic by Schneller, Jessica L et al.
REVIEW Open Access
Genome editing for inborn errors of
metabolism: advancing towards the clinic
Jessica L. Schneller1,2, Ciaran M. Lee3, Gang Bao3 and Charles P. Venditti2*
Abstract
Inborn errors of metabolism (IEM) include many disorders for which current treatments aim to ameliorate disease
manifestations, but are not curative. Advances in the field of genome editing have recently resulted in the in vivo
correction of murine models of IEM. Site-specific endonucleases, such as zinc-finger nucleases and the CRISPR/Cas9
system, in combination with delivery vectors engineered to target disease tissue, have enabled correction of mutations
in disease models of hemophilia B, hereditary tyrosinemia type I, ornithine transcarbamylase deficiency, and lysosomal
storage disorders. These in vivo gene correction studies, as well as an overview of genome editing and future
directions for the field, are reviewed and discussed herein.
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Background
Inborn errors of metabolism (IEM) are genetic disorders
typically caused by an enzyme deficiency. As a conse-
quence of the defect, insufficient conversion of substrate
into metabolic product occurs, which can produce
pathology by a variety of mechanisms, including the ac-
cumulation of toxic metabolites upstream of the block,
reduction of essential downstream compounds, feedback
inhibition or activation by the proximal metabolite on
the same or different pathway, or abnormal alternative
substrate metabolism [1]. Traditional therapies for IEM
aim to reduce substrates, remove toxic intermediates,
and/or supplement essential downstream products. Acti-
vation of alternative pathways for disposal of toxic inter-
mediates is also employed, as in the case of urea cycle
disorders [2], and for some conditions, enzyme replace-
ment therapy is available. While an understanding of the
pathophysiology of IEM has led to the development of
more focused treatments, the correction of the under-
lying genetic mutation still remains as the ultimate
therapeutic goal. With the advent of genome editing, a
single treatment offering permanent and effective ther-
apy may soon be realized. In this review, we discuss
recent examples of in vivo genome editing for correction
of preclinical models of IEM, disorders where the first
clinical applications of genome editing may likely be
implemented.
As the principal site for many intermediary metabolic
reactions, the liver is the main target organ to correct
for improving disease-related phenotypes [3]. Of the
three major cell types in the liver, the majority of cells
(~70%) are hepatocytes. The degree to which hepato-
cytes must be corrected to achieve therapeutic benefit
for a given IEM depends on factors intrinsic to the per-
turbed biochemical pathway, and enzymopathy. Some
disorders, such as hemophilia, require minimal activity
to correct the associated bleeding propensity, while
others, such as the proximal urea cycle disorder orni-
thine transcarbamylase (OTC) will require more activity,
and larger numbers of cells corrected, to normalize
metabolism [4]. Enzyme replacement via elective liver or
combined liver-kidney transplantation is considered for
conditions such as urea cycle disorders or organic acide-
mias when the clinical phenotype is severe [5–7]. Because
most metabolic diseases are caused by loss-of-function
mutations that occur in enzymes widely expressed in
hepatocytes, gene therapy may thus represent a treatment
option that could avoid the surgical complications of
transplantation, yet provide the full benefits of liver
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Adeno-associated viruses (AAVs)
The ideal gene transfer vector will safely and efficiently
deliver a therapeutic gene (transgene) only to cells of the
target tissue. Liver-directed gene therapy has historically
relied on the use of viral vectors because of their super-
ior efficiency in delivering transgenes to cells in vivo.
Due to promising characteristics associated with safety
and efficacy, AAV has emerged as the most promising
among viral vector candidates for preclinical gene ther-
apy studies targeting the liver.
AAV is a single-stranded DNA virus that has been
configured for use in gene therapy by removal of the
endogenous viral coding sequences, allowing transgenes
up to 4.7 kb to be inserted. AAV has a favorable safety
profile for clinical translation as a gene therapy vector.
AAVs have an absolute requirement for auxiliary genes
from a co-infecting adenovirus or herpes virus for repli-
cation and are therefore helper-dependent. Additionally,
wild-type AAV infections are poor activators of the im-
mune system [8] and are not recognized to cause human
disease. Because AAV is largely maintained as an epi-
some, the risk of insertional mutagenesis is greatly re-
duced compared to integrating vectors, such as those
based on retroviruses. AAV infection in human cells in
the absence of a co-infecting virus leads to a low level of
preferential integration at a locus on chromosome 19
known as AAVS1 [9]. In addition to these promising
safety features, AAV can transduce both dividing and
non-dividing cells, and is therefore effective in neonatal
as well as adult disease models. A most powerful feature
is that the AAV genome can be packaged within capsid
proteins, each demonstrating distinct tropisms, which
can greatly enhance the efficiency of gene transfer to
specific tissues. For example, pseudotyping of the AAV2
genome with the capsid from AAV serotype 8 can endow
a vector with the ability to completely transduce the liver
[10, 11]. To facilitate the characterization and applica-
tion of AAV, novel platforms for large-scale clinical-
grade vector production have been developed [12].
While much research has been performed proving the
efficacy of AAV as a gene therapy vector, more investiga-
tion is necessary to fully understand its safety profile.
Despite the great therapeutic potential of AAV vectors,
several studies have shown that low levels of AAV integra-
tion into the genome do occur and can exhibit genotoxic
effects [13, 14] dependent upon vector configuration and
dose [14]. The outcome of murine studies on the clinical
translation of AAV requires further investigation because
many vector integrations that were associated with he-
patocellular carcinoma (HCC) were located in a small,
non-conserved microRNA (miR341). Subsequently, an
unrelated study documented AAV2 integrations in
known cancer genes in 11 of 193 HCCs derived from
humans [15]. Because the majority of the 11 HCCs with
AAV integrations derived from the livers of non-cirrhotic
patients without known risk factors for HCC, the authors
suggested a role of AAV2 in HCC development. Until the
underlying mechanisms between AAV integrations and
HCCs are fully defined, the genotoxic potential of AAV
needs to be considered in future therapies relying on this
vector. One solution to mitigating AAV-mediated geno-
toxicity would be to use genome editing to either repair
the pathogenic mutation at the locus directly by targeting
integration of a therapeutic cDNA into the disease gene,
or correction into a “safe harbor”, a genomic locus not
known to be adversely affected by insertion and expres-
sion of an engineered transgene. Thus, genome editing
could mitigate the genotoxic effects of uncontrolled vector
integration. New genome engineering technologies are
making targeted genetic manipulations possible, and will
be discussed next, with representative examples.
Genome editing using site-specific endonucleases
The field of genome editing has evolved to address the
need for improving the efficiency and specificity of trad-
itional genome modification achieved by homologous re-
combination (HR). Genome engineering tools typically
introduce a double-stranded break at a specific target in
DNA, activating endogenous cellular repair pathways,
thereby increasing the frequency of HR by several orders
of magnitude [16, 17]. The double stranded break can
then be repaired by non-homologous end joining
(NHEJ), which leads to insertion or deletion of a small
number of nucleotides (indels) at the break, or corrected
via homology-directed repair (HDR), which can result in
specific base-pair changes when a donor template is
introduced at the site of the break [18–20]. Several gen-
ome editing technologies exist, with in vivo studies per-
formed to date relying on zinc-finger nucleases (ZFNs),
transcription activator-like effector nucleases (TALENs),
or the CRISPR-Cas9 system (Fig. 1). Zinc-finger nucle-
ases (ZFNs) were the first synthetically engineered gen-
ome editing reagents. ZFNs combine a FokI restriction
enzyme domain with a zinc-finger DNA binding module
to target double stranded breaks in DNA [21]. FokI func-
tions as a dimer; consequently, for genome editing,
ZFNs are designed in pairs that bind regions flanking
the target site [22]. TALENs emerged as an alternative to
ZFNs for genome editing. TALENs are similar to ZFNs
and comprise a non-specific FokI nuclease domain fused
to a customizable DNA-binding domain. This DNA-
binding domain is composed of highly conserved repeats
derived from transcription activator-like effectors, which
are proteins secreted by Xanthomonas spp. bacteria to
alter gene transcription in host plant cells [23]. More re-
cently, the clustered regularly interspaced short palin-
dromic repeats or CRISPR-Cas9 system was identified as
an RNA-guided immune system used by bacteria to
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protect against invading foreign viruses and other patho-
gens [24]. The CRISPR system from Streptococcus pyo-
genes, repurposed for genome engineering, consists of two
basic components, the Cas9 endonuclease (SpCas9) and a
guide RNA (gRNA). The gRNA contains a programmable
recognition domain capable of binding and cleaving any
genomic target proximal to a motif called the protospacer
adjacent motif (PAM), which is specific to the bacterial
strain from which the CRISPR system is derived. CRISPR
has evolved in a few short years to become a common
genome editing tool, used to manipulate genes in vitro
[25–27] and even to correct disease-causing mutations in
mouse models such as IEM, discussed below.
Many IEM are ideal candidates for genome editing cor-
rection because they are typically severe, liver-dominant
in terms of symptoms and pathophysiology, well-defined
in terms of clinical phenotypes, and yet have largely insuf-
ficient or inadequate therapy. For some, it is known that a
low level of gene correction could significantly ameliorate
the disease phenotype. Preclinical models of such disor-
ders include hemophilia B [28], hereditary tyrosinemia
type I [29], and ornithine transcarbamylase deficiency
[30]. Hemophilia B, in particular, has been a pillar of the
gene therapy field because the factor IX (FIX) gene fits
readily into an AAV, and a low-level of protein correction
leads to measurable improvements in biomarkers and
restoration of hemostasis. It logically has followed that
hemophilia B was the first disorder for which a preclinical
mouse model was corrected by genome editing [31]. This
study and subsequent studies utilizing genome editing for
correction of hemophilia B as well as other IEMs are
reviewed in the following section.
Preclinical models corrected via in vivo genome
editing
Hemophilia B
Individuals most severely affected by hemophilia B ex-
hibit circulating levels of blood clotting FIX below 1% of
normal, leading to sporadic hemorrhaging from the time
of birth [32, 33]. Restoration of FIX to more than 1% of
normal, however, converts the disease to a more mild
form, making hemophilia a powerful model to assay
Fig. 1 Schematic of genome engineering technologies (left) and DNA repair pathways resolving double-stranded DNA breaks (right). a Zinc-
finger nucleases (ZFNs), b TALENs, and c the CRISPR/Cas9 system produce DNA cleavage at a desired genomic target. Once cleavage occurs,
insertion of a donor template with homology to the cut site can lead to gene correction via the homology directed repair (HDR) pathway. In the
absence of a donor, the random insertion or deletion of nucleotides characteristic of the non-homologous end-joining (NHEJ) pathway can result
in targeted mutagenesis
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correction using genome editing approaches. A founda-
tional study for in vivo genome editing used zinc-finger
nucleases (ZFNs) to target the first intron of the FIX
gene in neonatal mice, with the goal of inducing suffi-
cient levels of HDR into the FIX locus [31]. A human-
ized murine model of hemophilia B was generated by
expressing a mutant human FIX (hFIX) knocked-into
the Rosa26 locus on the background of a homozygous
FIX deletion mouse. ZFNs were delivered by a single
AAV serotype 8 vector designed to target the liver, the
major site of synthesis for FIX. A second AAV8 deliv-
ered a promoterless cDNA encoding exons 2–8 pre-
ceded by a splice acceptor site; this rescue cassette was
engineered to recombine into the first intron of the FIX
gene after ZFN cleavage. Upon perfect recombination,
splicing of the FIX minigene behind the endogenous FIX
exon 1 led to expression of functionally active FIX. In
mice treated as neonates, HDR was measured at 1–3%,
and FIX protein expression measured at 3–7%. Although
indels produced by the ZFNs in the intron did not inter-
fere with the creation of functional protein after HDR,
the frequency of off-target cleavage by the ZFN pair,
measured at up to 4%, and the lower overall efficiency of
correction required that this approach be further opti-
mized for clinical translation. Nevertheless, it was the
first study to prove that genome editing could be used in
vivo to correct a mammalian model of a disease.
Two studies sought to improve upon the design by
directing the therapeutic transgene into albumin, an
ideal safe-harbor locus due to its high transcriptional
activity, and corresponding increased efficiency of inte-
gration by homologous recombination. Furthermore, a
transgene correctly inserted into this locus would be
expressed from the endogenous and liver-specific Alb
promoter. Both studies aimed to introduce promoterless,
partial cDNAs of hFIX into the albumin locus in mouse
models of hemophilia B using the liver tropic AAV sero-
type 8 as the delivery vector, but different regions of the
Alb gene were targeted, and different editing strategies
employed.
In an extension of the genome editing study that
aimed to correct hemophilia B at the disease locus, the
first intron of the albumin gene was selected for inser-
tion of a partial hFIX cDNA [34]. The ZFN pair target-
ing intron 1 was delivered on a single vector, with a
second vector carrying the hFIX cDNA rescue cassette
of exons 2 to 8. Adult C57Bl6 mice treated with 1 ×
1011vg AAV8-ZFNs or 5 × 1011vg AAV8-hFIX-donor
exhibited high circulating hFIX levels despite a low level
of integration; the mAlb-hFIX mRNA corresponded to
0.5% of total wild-type mAlb mRNA transcripts.
Although HDR commonly occurs during the S and G2
phases of the cell cycle, when cells are dividing, these re-
sults suggest that insertion of a donor sequence via
NHEJ and ligation is an effective correction method in
the adult liver, when cells are quiescent and more prone
to DNA repair by NHEJ. Additionally, only a small num-
ber of hepatocytes need to be modified at the albumin
locus in order to achieve clinically relevant levels of
hFIX.
In the second study, the disruption to albumin expres-
sion was minimized by mediating HR of a corrected par-
tial cDNA donor flanked by arms of homology without
the use of site-specific endonucleases [35]. Additionally,
the hFIX cDNA was expressed as a 2A-fusion at the end
of the Alb reading frame, 5’ to the Alb stop codon. Thus,
both albumin and FIX were co-expressed from a single
mRNA transcript and processed into two separate pro-
teins, both containing a signal peptide for secretion.
Because neither the FIX nor the 2A peptide contained a
methionine residue, off-target integration of the con-
struct did not lead to hFIX expression. Targeted Alb al-
leles versus wild-type Alb alleles were measured at 0.5%
on average for mice injected as neonates or adults at the
highest dose and both neonatal and adult mice treated
the rAAV8-donor showed hFIX protein levels in plasma
at 7–20% of normal, with clotting activity similar to
wild-type mice 2 weeks post-treatment. Targeted inte-
gration without the use of site-specific endonucleases
may therefore mitigate off-target effects and the possibil-
ity of genotoxicity, but the accompanying increase in
vector dose required (by up to an order of magnitude in
adult mice) may pose concerns related to immune
activation and manufacturing. Whether mice treated as
neonates develop HCC by any of the aforementioned
vectors remains to be determined, but will be critical to
examine. Taken as a whole, the genome editing studies
using hemophilia models demonstrate the potential for
genome editing to be applied to other IEM for which a
low level of corrected gene expression can lead to ameli-
oration of the disease phenotype, such as lysosomal
storage disorders.
Hereditary tyrosinemia type I (HT-I)
HT-I is caused by mutation of fumarylacetoacetate
hydrolase (FAH), the last enzyme in the tyrosine cata-
bolic pathway. FAH deficiency causes accumulation of
fumarylacetoacetate in hepatocytes and results in severe
liver damage. Affected individuals fail to gain weight and
grow at the expected rate, which is recapitulated by the
Fah–/– mouse model [29, 36]. Current therapies for HT-
I include nitisinone (NTBC), which inhibits hydroxyphe-
nylpyruvate dioxygenase (HPD), the enzyme catalyzing
the second step of tyrosine catabolism. Removal of
NTBC from the diet of mutant mice results in the ex-
pansion of repaired hepatocytes that repopulate the liver,
a unique characteristic of this disease model which
makes it useful for testing the efficacy of novel genome
Schneller et al. BMC Medicine  (2017) 15:43 Page 4 of 12
editing therapies [36], because it allows selection of cells
that have been corrected in vivo. In the first study using
CRISPR to correct a disease model in vivo [37], CRISPR
components were systemically delivered via hydrodynamic
tail vein injection in a mouse model of hereditary tyrosine-
mia type I. The Cas9 enzyme from S. pyogenes and one of
three gRNAs (FAH1, FAH2 or FAH3) were co-injected
with a short single-stranded DNA oligo donor template
into adult Fah–/– mice. Animals receiving the FAH2 guide
targeting in the intron just downstream of the point muta-
tion did not lose weight after NTBC-containing water was
withdrawn, while untreated Fah–/– mice experienced rapid
weight loss after NTBC withdrawal, and then death. Due
to the selective advantage conferred after successful edit-
ing at the Fah locus, a correction of 0.4% was sufficient to
rescue the treated mutant mice from lethality; 30 days
after NTBC withdrawal, 33.5% of hepatocytes were Fah
+ in treated mice. Follow-up studies aimed to improve
the efficacy and mode of delivery for clinical implemen-
tation. By coupling transient non-viral delivery methods
with pharmacological selection, a follow-up study was
able to achieve a more than ten-fold increase in cor-
rected hepatocytes [38].
In a complementary approach using AAV gene deliv-
ery, HDR-mediated rescue of a point mutation in the
Fah gene was accomplished using an AAV8 vector to
deliver the FAH2 guide RNA and a HDR template
(AAV-HDR) [38]. The SpCas9 mRNA was packaged into
a lipid nanoparticle (nano.Cas9) for short-term expres-
sion, reducing the chance of genotoxic off-target effects.
Fourteen days post-treatment, a greater than 6% correc-
tion of Fah+ hepatocytes was detected in treated Fah–/–
mice. Highly efficient delivery vectors led to a significant
increase in the initial correction of Fah over the initial
treatment, and completely restored the liver by 1 month.
An alternative approach has leveraged the potent gene
inactivating capability of the CRISPR system to target an
enzyme upstream of FAH in the tyrosine catabolic path-
way, HPD, as an alternative method of correcting the
Fah–/– mouse model. Metabolic reprogramming by knock-
out of the HPD enzyme would convert HT-I to a milder
disorder, HT-III. As predicted, Fah–/–; Hpd–/– mice show
reduced risk of HCC compared to Fah–/– mice treated
with NTBC; thus, bypassing this pathway via deletion of
the HPD gene could be an effective treatment for HT-I
patients [39]. To test this premise, CRISPR components
designed to inactivate HPD were delivered to adult Fah–/–
mice [40]. Assessment of editing efficiency by staining cells
for Hpd expression showed that bi-allelic knockout at
1 week post-treatment was 8%. At 4 weeks, the efficiency
increased to 68% due to the positive selection of Hpd–/–
hepatocytes, and treated mice phenotypically resembled
wild-type mice at 25–27 days post withdrawal of NTBC.
In some mice, healthy hepatocytes completely replaced
diseased cells by 8 weeks post-treatment. As with direct
correction at the Fah locus, the success of this strategy
was contingent upon the positive selection inherent to the
HT-I model, and provided the incentive for testing artifi-
cial methods of induced selection to enrich for desired
editing events in modified hepatocytes.
Improving the efficacy of genome editing is a pervasive
problem independent of targeting strategy and delivery
method. Although the previous examples are encour-
aging, they are applicable only in the rare setting in
which healthy hepatocytes have a selective growth ad-
vantage, such as in HT-I. For most liver diseases, this is
not the case, and a method of selecting for cells would
allow the amplification of less efficient gene correction.
To this end, a novel approach using a small molecule
and gene editing has been used to induce a transient
state of superior fitness in corrected hepatocytes. Critical
to the success of this study has been the use of a transition
state analogue and potent inhibitor of FAH, CEPHOBA,
which can induce a transient HT-I [41], and the previous
observation that shRNA-mediated knockdown of an alter-
nate enzyme in the pathway, Hpd, can positively select he-
patocytes in the HT-I mouse model [42]. To recapitulate
positive selection in wild-type mice, an rAAV8 cassette
was designed with an Hpd shRNA (shHpd) embedded in a
miRNA so that it would be expressed only after perfect re-
combination into the albumin gene. Co-delivery of the
hFIX cDNA fused to a 2A peptide on the same vector
allowed for facile assaying of HDR events at the Alb locus.
The dual expression construct was administered to neo-
natal C57Bl6 mice, and at 4 weeks of age, CEPHOBA was
injected daily for 4 weeks to enrich for gene targeted cells.
In two of three mice, hFIX levels steadily increased and
were stable in the therapeutic range but declined in a
third. With a second round of CEPHOBA, however, hFIX
was expressed in the therapeutic range for all three mice.
shRNA-mediated knockdown of Hpd thus protected he-
patocytes against the effects of the FAH inhibitor
CEPHOBA. Although efficiency of HR with this method
was less than 1%, after selection, transgene-expressing
cells constituted 50% of the liver. Any transgene delivered
in cis to the protective shRNA could be co-selected, mak-
ing the “GeneRide” construct a malleable instrument
applicable to other metabolic diseases, with fewer con-
cerns of off-target integration.
Ornithine transcarbamylase (OTC) deficiency
OTC deficiency, an X-linked disease, is the most com-
mon urea cycle disorder. Affected individuals generally
possess little or no functional OTC enzyme, but restor-
ation of as little as 3% activity can significantly improve
the disease phenotype [43]. The spfash OTC mouse
model recapitulates the hyperammonemia commonly
seen in patients when stressed with a high protein
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diet, due to residual levels of OTC activity (~5%) in
these mice [30]. To accomplish therapeutic editing in
vivo at the Otc locus, an SaCas9/gRNA system was used
to correct a disease-causing mutation in the spfash mice
[44]. SaCas9 under expression of the liver-specific TBG
promoter was packaged into a serotype-8 capsid and co-
delivered with a second AAV8 carrying the gRNA cas-
sette and a donor template. In mice treated as neonates,
10% of Otc alleles were corrected and Otc enzyme activ-
ity was restored to 20% and 16% at 3 and 8 weeks, re-
spectively, in liver homogenates. All of the mice treated
as neonates survived a 1-week high protein stress test,
and manifested significantly lower ammonia levels com-
pared to untreated spfash mice, where one-third of con-
trol spfash mice died or had to be euthanized when
treated in an identical fashion. In comparison to the
neonatal mice, spfash mice treated as adults exhibited
higher levels of NHEJ, with deletions large enough to ex-
tend into the adjacent exon. Although all treated adults
displayed effects of Otc deficiency, the higher doses of
AAV were more severe, culminating in termination of
the experiment at 2 weeks. These animals showed ele-
vated levels of plasma ammonia, suggesting that editing
presumably led to increased mutations in the Otc gene,
causing substantial loss of Otc activity and leading the
mice to succumb to the resultant hyperammonemia.
Such an outcome emphasizes the importance of further
characterizing DNA repair in vivo after genome
manipulation.
Lysosomal storage disorders
The proof-of-concept studies reviewed above clearly dem-
onstrate the therapeutic potential of genome editing ap-
proaches. Future success will depend on identifying and
implementing correction strategies applicable to a broad
range of disorders, such as insertion of a therapeutic
transgene at a safe harbor locus. The same system using
ZFNs to insert a cDNA into the albumin locus also led to
a similar approach to treat two lysosomal storage disor-
ders [34]. Preclinical studies performed in Hurler and
Hunter syndrome mouse models demonstrated high activ-
ity levels of alpha-L-iduronidase and iduronate sulfatase,
respectively, in liver and plasma post-treatment with a sin-
gle dose of two AAVs – one to deliver the Alb ZFNs, and
the other a cDNA donor to correct the enzyme defect. A
unique feature of certain lysosomal storage disorders is
that cross correction, i.e., the restoration of enzyme activ-
ity in uncorrected tissues that take up the secreted enzyme
from the circulation, can be observed. The data suggests
that therapeutic levels of alpha-L-iduronidase and iduro-
nate sulfatase produced in the liver could have widely
beneficial effects.
In addition to albumin, there is the potential for integra-
tion into other safe harbor loci. Targeting of the glucose-
6-phosphatase (G6PC) cDNA into the Rosa26 locus using
ZFNs led to increased survival in a mouse model of glyco-
gen storage disease type Ia (GSD1a) [45]. A dual AAV sys-
tem was employed, with one vector delivering ZFNs and a
second the G6PC transgene. While 8-month-old knockout
mice showed improved survival, from 43% to 100%, when
components were delivered with serotype 8 vectors, cor-
rection of standard GSD1a biomarkers was observed only
when components were delivered via AAV serotype 9.
Interestingly, there appeared to be a selective advantage
for stably transduced G6P-ase expressing hepatocytes, as
determined by an increase in allele modification for
treated knockout mice versus treated wild-type litter-
mates, a phenomenon not previously observed. This study
establishes Rosa26 as a safe harbor locus for transgenesis
via gene targeting in alternate murine disease models. In
human-derived models, parallel efforts have successfully
integrated therapeutic cDNA into the AAVS1 site in stem
cells [46] and T cells [47]; the ongoing transcriptional ac-
tivity of transgenes inserted in AAVS1 makes it a plausible
target [48]. Murine and rodent models have been gen-
erated carrying the AAVS1 locus [49] and could serve
to test future AAVS1-targeting genome editing plat-
forms. Table 1 summarizes the studies performed to
date that have successfully employed in vivo genome
editing to correct or ameliorate disease manifestations
in mouse models of IEMs.
Alternative strategies – the genome editing
toolbox
Improvements to CRISPR and new reagents
Expression of genome editing components in a manner
that is both efficient and non-toxic to the cell presents a
barrier to application of most editing systems in vivo.
The well-characterized CRISPR/Cas9 from S. pyogenes is
encoded by a cDNA of 4.2 kb, and while feasible to
package in an AAV, is too large for inclusion of the regu-
latory elements that would lead to enhanced levels of
protein expression. By identifying and characterizing
orthologous Cas9 proteins such as those from S. thermo-
philus (StCas9) [50], N. meningitidis (NmCas9) [51], and
S. aureus (SaCas9) [52], which are smaller in size but
show similar activity to the SpCas9, the Cas9 nuclease
can now be packaged efficiently.
The identification and characterization of distinct
CRISPR systems could expand the genome editing tool-
box to engineer sites not previously amenable. The well-
studied Cas9 CRISPR systems are classified as class 2 type
II systems. A putative class 2 type V system has been
identified, possessing an endonuclease domain known as
Cpf1 [53]. Unlike Cas9, Cpf1 introduces a staggered,
double-stranded DNA break distal from the PAM. Inser-
tion of a donor template having complementary overhangs
to such a staggered break could be significantly more
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efficient than repair of the blunt-ended DNA breaks pro-
duced by Cas9, leading to increased hepatocyte correction
in disease models. Two Cpf1 orthologs were initially char-
acterized and shown to have activity in a human HEK293
cell line. These orthologs have been further assayed in two
independent studies for their on-target activity and
genome-wide specificity [54, 55]. Both studies showed that
the Cpf1 endonuclease from Lachnospiraceae bacterium
(LbCpf1) and Acidaminococcus sp (AsCpf1) exhibit robust
mutagenicity in human cell lines. Sites in the DNMT1
gene were assayed for on-target specificity. Both studies
identified nucleotides 1–18 downstream from the PAM as
Table 1 Summaries of genome editing studies performed on preclinical models of inborn errors of metabolism
IEM Summary Comment Reference
Hemophilia B Targeting FIX disease locus
Dual AAV8 vectors:
Zinc-finger nucleases (ZFNs)
Partial FIX cDNA
Neonatal, hemophilia B mouse
model
First in vivo study using therapeutic genome
editing
Low rates of homology-directed repair (HDR)
detectable off-target events (<4%)
Li et al., 2011 [33]
Hemophilia B Targeting Alb safe harbor
Dual AAV8 vectors:
ZFNs
Partial FIX cDNA
Adult C57BL/6+ hemophilia B
mouse models
Low rate of NHEJ-mediated correction (0.5%
fused mRNA transcripts)
Due to integration in Alb, secretion of
corrected protein led to therapeutic levels
of circulating FIX
Duration of effect 12 weeks after single
treatment
Sharma et al., 2015 [34]
Hemophilia B Targeting Alb safe harbor
No endonuclease
Single AAV8 vector targeting
FIX donor as 2A fusion to Alb
Neonatal + adult hemophilia
B mice
No off-target
Low rate of HDR (0.1% fused mRNA
transcripts)
Addition of amino-terminal proline to FIX
due to 2A peptide
Barzel et al., 2015 [35]
Hereditary Tyrosinemia Type I Targeting Fah disease locus
CRISPR: SpCas9/gRNA + ssDNA
oligonucleotide
Naked DNA
Positive selection of hereditary tyrosinemia
type I (HT-I) mouse model
Low HDR (0.4%); increased to 33.5% after 30
days
Off-target for Fah gRNA < 0.3% (NIH3T3 cells)
Yin et al., 2014 [81]
Hereditary Tyrosinemia Type I Targeting Fah disease locus
CRISPR: SpCas9 mRNA, LNP
delivery (nano.Cas9)
FAH2 gRNA + donor (AAV-HDR)
Transient expression SpCas9 (LNP)
HDR 6% without selection
Low level off-target cutting (Hepa1-6 cells)
Yin et al., 2016 [37]
Hereditary Tyrosinemia Type I Targeting Hpd (disease locus)
CRISPR: SpCas9 + 2 gRNAs
non-homologous end joining
(NHEJ)
Naked DNA
Positive selection of HT-I mouse model
Metabolic reprogramming
Multiplex editing (2 guides)
8% NHEJ efficiency at both cut sites 1-week
post
68% efficiency 4-weeks
post (+ selection)
Pankowicz et al., 2016 [39]
Hereditary Tyrosinemia Type I Targeting Alb safe harbor
No endonuclease
rAAV8: Hpd shRNA + hFIX
C57Bl/6 wild-type mice
Inducible positive selection using CEPHOBA
Initial homologous recombination < 1%;
after selection 50%
Nygaard et al., 2016 [41]
Ornithine Transcarbamylase
Deficiency
Targeting Otc disease locus
CRISPR: SaCas9 + gRNA
Dual AAV8 vectors:
SaCas9 + gRNA-donor Otc
mouse model
Smaller Cas9 orthologue
S. aureus
10% HDR in neonatal mice
Large deletions in adult mice ➔
hyperammonemia
Yang et al., 2016 [43]
Lysosomal Storage Disorders
(MPSI, MPSII)
Targeting Alb safe harbor
Dual AAV8 vectors:
ZFNs + donor
C57Bl/6 wild-type mice
Therapeutic protein detectable by Western
blot
Phase I clinical trial MPSI:
3 AAV6 vectors:
ZFN + ZFN + donor
Sharma et al., 2015 [34]
Glycogen Storage Disorder
Type Ia
Targeting Rosa26 safe harbor
Dual AAV8/AAV9
ZFNs + donor
GSD1a mouse model
AAV8: Improvement in survival
AAV9: Improvement in biochemical
phenotype
Positive selection of corrected hepatocytes
Landau et al., 2016 [44]
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necessary for Cpf1 activity; double mismatches in this re-
gion abrogated Cpf1-mediated indels. Both studies also
found that, at the sites assayed, Cpf1 showed greater fidel-
ity than SpCas9 without being less efficient. Whether
AsCpf1 and LbCpf1 are as effective at cleaving DNA
targets at other sites in the genome, and with superior
specificity, remains to be investigated.
In addition to DNA editing, new native and synthetic
CRISPR systems are being identified and engineered for
manipulating RNA. L. shahii C2c2 is a putative class 2
type VI system which cuts RNA via two HEPN RNase do-
mains [56]. C2c2 cleaves ssRNA dependent on target se-
quence and secondary structure. Interestingly, C2c2 is
activated not only to cleave its intended target, but once
active, indiscriminately cleaves RNA in a non-specific
manner culminating in programmed cell death (PCD). A
more detailed understanding of the mode by which C2c2
induces PCD would allow C2c2 to be used to trigger PCD
or dormancy in specific cells such as cancer cells express-
ing a particular transcript or cells infected by a specific
pathogen. The application of C2c2 in this manner would
require absolute on-target specificity.
Elucidation of the mechanisms by which Cas9 targets
and binds DNA has led to engineering of novel Cas9 vari-
ants with improved range or improved specificity. By ma-
nipulating the PAM recognition domain, Cas9 variants
with expanded target ranges have been generated [57, 58].
Additionally, amino acid mutations have been introduced
in the endonuclease to reduce non-specific DNA binding,
improving specificity [59]. Capitalizing on CRISPR’s ro-
bust DNA-recognition ability, a new technology executes
conversion of a single DNA base pair from cytosine to
uracil [60]. This technology, designated as base editor,
fuses the cytidine deaminase enzyme APOBEC1 to a cata-
lytically inactive Cas9 (dCas9) endonuclease (BE1). Using
insights from CRISPR’s DNA binding and cleavage mech-
anisms, BE1 has been enhanced in subsequent generations
(BE3). The BE3 system successfully corrected a single base
pair mutation after nucleofection in two cell culture dis-
ease models, at higher efficiencies and with lower indel
formation than the wild-type SpCas9 plus a donor ssDNA.
A hindrance to the application of this technology is that
the base editor converts any cytosine in the target site,
thereby requiring strict target selection. Additionally, off-
target indels are replaced by off-target C-U conversions
that might be more frequent given the higher efficiency
compared to SpCas9 at the on-target site. Further adjust-
ment to reduce the base pair conversion window, com-
bined with careful target selection, would be required to
refine this technology for translational use.
Tissue-specific genome editing
Genome editing in the brain and other tissues of the central
nervous system is of paramount interest for neurodegenerative
diseases as well as lysosomal storage disorders, but gene trans-
fer has proven difficult due, in part, to the blood brain barrier.
An in vivo study quantified the efficiency and nature of indels
in primary neurons after AAV-mediated delivery of SpCas9
[61]. MeCP2, a protein ubiquitously expressed in the brain
and implicated in Rett syndrome, was successfully
knocked-down in adult male C57BL6 mice, with indel
levels as high as 67.5%. Multiplex genome editing from
a dual-AAV vector system enabled concurrent knock-
down of Dnmt1, Dnmt3a, and Dnmt3b, genes respon-
sible for memory formation and learning. Simultaneous
editing of the three loci was observed in approximately
35% of all transduced neurons with only 0–1.6% off-target
cleavage. The ability to manipulate multiple genes in a
tissue-specific context, and in the brain in particular,
should allow for further elucidation of disease-related
gene function and could ultimately lead to simultaneous
correction of multiple mutations.
Duchenne muscular dystrophy (DMD) is a progressive
muscle degenerative disease caused by mutations in the
dystrophin gene that disrupt the reading frame and lead to
loss of functional dystrophin expression. Milder forms of
DMD are caused by in-frame deletions in the dystrophin
gene, resulting in expression of a truncated but partially
functional protein. Therapies that aim to restore the dys-
trophin reading frame could therefore be effective. Three
independent studies used CRISPR to restore the reading
frame in the mdx mouse model of DMD, which expresses a
truncated dystrophin [62]. In one study, two AAV8 vectors
separately delivered SaCas9 and two gRNAs targeting the
intronic regions flanking the mutated exon 23. Exon 23 was
shown to be deleted from 2% of alleles, with only 3% indels
at the target site and less than 1% indels at the top off-
target site for both guides [63]. A second study used a simi-
lar design but delivered CRISPR components using a sero-
type 9 vector, which efficiently transduces skeletal and
cardiac muscle. SaCas9 activity was enhanced by modifica-
tion of the gRNA scaffold, which led to improved exon 23
excision (39% by deep sequencing) with minimal off-target
activity [64]. A third study used AAV9 vectors, but deliv-
ered the SpCas9 under expression of a truncated promoter,
with the two guide RNAs on a separate vector. Dystrophin
expression at up to 25% was restored in myofibers as mea-
sured by immunostaining [65]. Dystrophin expression as
low as 3–15% can alleviate pathogenesis in cardiac and
skeletal muscle; thus, these studies demonstrate the benefit
of using CRISPR for in vivo multiplex editing of disease
models showing tissue-specific pathology.
Conclusions
Hurdles and future directions for genome editing
therapeutics: the 0.1%
As CRISPR-Cas9 approaches the clinic, understanding the
host response to the Cas9 protein and AAV vector
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components is essential. Delineating these responses and
developing strategies to manage them will be critical to
achieving clinical success. Although AAV are capable of
priming CD8+ T cell responses towards a transgene, lack
of co-stimulatory signals can result in impaired prolifera-
tion and cytokine secretion, generating passive tolerance
[66–68]. However, a certain degree of inflammation due
to factors such as serotype can yield a robust CD8+ re-
sponse [69]. A recent study attempted to characterize the
host response to AAV9-delivery of a split Cas9 system, for
which the Cas9 coding sequence was distributed between
two vectors and reconstituted post-translationally [70].
Cas9 expression in the tibialis interior muscle of adult
male C57Bl6 mice increased the frequency of antigen-
specific T-cells among injected mice; Cas9-specific anti-
bodies were also observed. The vector stimulated AAV
capsid-specific antibodies, but in contrast to Cas9, the epi-
topes were shared between individually treated animals.
Two weeks after administration, no significant muscle cell
damage or repair response was observed despite the pres-
ence of CD8+ T cells. Managing the host response to
AAV-delivery of CRISPR components will rely on under-
standing the implications of immune activation when cell
damage may yet be undetectable. Determining whether
host immune response to AAV-Cas9-CRISPR interferes
with on- and off-targeting, as well as studying the host
response in clinically relevant disease models, requires
further study.
An important safety issue for genome editing is the
accurate assessment of off-target cleavage by endonucle-
ases and mitigating the effects of non-specific activity.
Understanding the interaction between synthetic editing
systems and DNA cleavage has led to the development
of algorithms to appraise likely off-target activity [71–73].
In general, genome editing systems found to be highly
effective at mediating on-target cleavage conversely
tend to show increased off-target activity. High fidelity
Cas9 variants have reduced on-target activity and non-
specific interaction with the DNA backbone thereby
diminishing the overall affinity of a Cas9/gRNA com-
plex for a particular on-target or off-target site [59].
This is important for gene repair systems relying on
HDR, where a high number of cutting events must
occur to achieve even a modest level of therapeutic
correction. In a recent study targeting correction of
the β-globin gene implicated in sickle-cell disease,
hematopoietic stem/progenitor cells were edited ex
vivo using a ribonucleoprotein complex of recombinant
Cas9 protein and an in vitro transcribed gRNA [74]. Des-
pite appreciable levels of HDR in CD34+ hematopoietic
stem/progenitor cells, off-target activity of up to 80% was
measured at the top-scoring site (OT1), with chromo-
somal translocations occurring between the on-target and
off-target sites. To reduce off-target effects, two high-
fidelity Cas9 variants were tested. These variants did not
lead to indel formation at OT1, but exhibited a five-fold
decrease in indels at the on-target site, leading to the use
of the wild-type Cas9 for further experimental use. An-
other approach to reducing or eliminating off-target activ-
ity is through the use of the StCas9, NmCas9, and SaCas9
orthologs. These orthologs recognize longer PAM se-
quences relative to the widely used SpCas9 system, and
therefore have a longer recognition sequence. This in-
creased length requirement reduces the frequency of po-
tential off-target sites within the genome and several
studies have shown that these Cas9 orthologs have less
off-target effects when tested in a direct comparison with
SpCas9 [75–77]. Until more powerful high-fidelity Cas9
variants are engineered, the use of promiscuous wild-type
Cas9 endonucleases in combination with assaying for off-
target cleavage remains the method of choice for gene cor-
rection studies.
Although adeno-associated viral vectors have been
utilized substantially for in vivo delivery of genome edit-
ing components, limitations are associated with these
vectors, including reduced DNA packaging capacity and
the potential for long-term expression of the dispatched
endonuclease. Non-viral gene therapy vectors have the
potential to address these limitations, particularly with
respect to safety. Vectors such as lipid nanoparticles
formulated with improved polymers can lead to transi-
ent in vivo expression of the well-characterized SpCas9,
reducing the hazards posed by off-target effects and host
immune response while improving genome editing
efficiency [38]. Alternative delivery of CRISPR compo-
nents as ribonucleoproteins with single-stranded DNA
donors would be a more economical method of rapid,
highly efficient gene manipulation [74]. Enhancement
and innovation of non-viral delivery of genome editing
reagents could address many of the current safety issues
surrounding the in vivo applications of CRISPR-Cas9
technology.
Correction of a disease-causing mutation from a single
treatment given at birth is the goal towards which
genome editing therapies for IEM are directed. The
widespread implementation of newborn screening has
made it possible to detect a number of IEM at a pre-
symptomatic stage when medical intervention has the
ability to alter the natural history of the disease. Now, as
the field of genome editing matures, the objective of the
field appears within reach; specifically, the correction of
a mutation at the endogenous locus. To that end, the
rapid development of highly specific Cas9 orthologs that
can be efficiently packaged into AAV is encouraging as
are improvements in non-viral delivery platforms. How-
ever, current genome editing practices have shortcom-
ings – most rely on cellular repair pathways that are not
well understood, leading to low efficiency of correction
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and an unintended alteration of non-targeted coding
sequences. A more thorough comprehension of DNA
repair mechanisms after cleavage by Cas9 and other
CRISPR systems should improve genome editing specifi-
city, while the development of novel selection strategies
that give a competitive advantage to gene-corrected cells
could reduce some of the issues with efficiency.
Already, a better understanding of CRISPR mecha-
nisms has led to improvements in the technology.
Temporal control over CRISPR expression has been
achieved with the development of a chemically inducible
CRISPR system [78]. By modifying Cas9 to high-fidelity
variants, as well as fusing catalytically inactive Cas9 to a
FokI endonuclease domain, the specificity has improved
[59, 79]. In a Cas9 devoid approach, triplex-forming pep-
tide nucleic acids have mediated HDR repair, and when
delivered via polymer nanoparticles with a donor tem-
plate, enabled up to 4% gene editing in thalassemic mice
[80]. Recently, genome editing has been applied in the
clinic to HIV [80], a fatal infection whose current treat-
ment regimen involves a cocktail of toxic drugs, taken
for the life of the patient. ZFNs designed to eradicate ex-
pression of chemokine receptor 5 (CCR5), a co-receptor
commonly used by HIV for entry into CD4 T cells, report-
edly increased the median CD4 T cell count by three-fold
in study participants, augmenting their natural anti-viral
immunity [81]. Initial therapeutic applications of genome
editing such as this one have relied on its effectiveness at
mediating gene knockout; achieving precise gene correc-
tion will require improvements. As CRISPR technology
upgrades, the enhancement to efficiency and safety will
bring genome editing closer to the clinic for patients with
IEMs, especially those in need of improved therapies.
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